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ABSTRACT
Objectives: To evaluate the health outcomes and
economics associated with the current guidance
relating to the prevention of falls in the elderly through
vitamin D supplementation.
Setting: UK.
Participants: UK population aged 60 years and above.
Interventions: A Markov health state transition model
simulated patient transitions between key fall-related
outcomes using a 5-year horizon and annual cycles to
assess the costs and benefits of empirical treatment
with colecalciferol 800 iu daily.
Primary and secondary outcome measures:
Costs and health outcomes attributable to fall
prevention following vitamin D supplementation.
Results: Our model shows that treating the UK
population aged 60 years and above with 800 iu
colecalciferol would, over a 5-year period: (1) prevent
in excess of 430 000 minor falls; (2) avoid 190 000
major falls; (3) prevent 1579 acute deaths; (4) avoid
84 000 person-years of long-term care and (5) prevent
8300 deaths associated with increased mortality in
long-term care. The greatest gains are seen among
those 75 years and older. Based on reduction in falls
alone, the intervention in all adults aged 65+ is
cost-saving and leads to increased quality adjusted life
years. Treating all adults aged 60+ incurs an
intervention cost of £2.70bn over 5 years, yet produces
a −£3.12bn reduction in fall-related costs; a net saving
of £420M. Increasing the lower bound age limit by
5-year increments increases budget impact to
−£1.17bn, −£1.75bn, and −£2.06bn for adults 65+,
70+ and 75+, respectively.
Conclusions: This study shows that treatment of the
elderly UK population with colecalciferol 800 iu daily
would be associated with reductions in mortality and
substantial cost-savings through fall prevention.
INTRODUCTION
Vitamin D is increasingly recognised as an
important sterol hormone with ubiquitous
expression of the vitamin D receptor
throughout the body’s organs.1 While the
effects of vitamin D on bone are well recog-
nised there is increasing appreciation of its
extraskeletal effects.2 Indeed, vitamin D deﬁ-
ciency is implicated in diseases beyond
calcium metabolism such as diabetes,
multiple sclerosis and cancer.2 With a high
prevalence of vitamin D deﬁciency and insuf-
ﬁciency in the general population, increasing
attention is turning to the positive impact of
vitamin D replacement therapy.
Meta-analytic data reveal that vitamin D
treatment is associated with reduced risk of
fractures in the elderly only in doses at or
above roughly 800 iu daily.3 Yet, these conclu-
sions are disputed, as others argue that
aetiological mechanisms such as bone min-
eralisation is unchanged through vitamin D
intervention.4 However, falls are a particu-
larly important event in the aetiology of frac-
tures, as well as contributing to other
morbidities, hospitalisation and institutional-
isation in the elderly. Again, the data regard-
ing falls has been confounded by inclusion
of data relating to different doses, additional
calcium supplementation and length of
study.5 A meta-analytic study suggested a sig-
niﬁcant reduction in the risk of falls in
Strengths and limitations of this study
▪ Age-group specific determination of health costs
related to falling.
▪ A conservative health economic model which
interprets current guidance on prevention of falls
using vitamin D therapy is highly cost effective
in the treatment of adults over a 5-year time
horizon.
▪ Conservative estimation of costs of falls present-
ing to accident and emergency (A+E) only.
▪ Fall prevention with empirical vitamin D 800 iu
daily is associated with a reduced mortality com-
parable to that found in meta-analyses.
▪ The role of vitamin D in fall prevention remains
controversial.
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elderly participants only in studies using doses of 700 iu
of vitamin D or above.6 Again, the study has been criti-
cised, yet a more recent review of the data by the
American and British Geriatric Societies conclude that
vitamin D therapy should be given to elderly participants
at risk of falls and at a dose of at least 800 iu per day.7
They conclude that the number needed to treat (NNT)
to prevent one fall is 10 compared with a NNT of 13
associated with exercise training. While evidence points
to doses of at least 800 iu daily in fall prevention strat-
egies in elderly participants, a letter from the Chief
Medical Ofﬁcers in the UK recommends a smaller dose
of 400 iu daily for all participants over 65 years of age at
risk of vitamin D deﬁciency.8
Universal vitamin D supplementation in older adults
has been found to be a cost-effective strategy for fall pre-
vention in the USA,9 and also in Western European
populations (including the UK) but using fractures as
the primary modiﬁable outcome.10–12
While the data suggest a positive impact of vitamin D
therapy on fall prevention, there are no data which
interpret the ﬁnancial impact of vitamin D treatment on
the UK population. Thus, based on the American
Geriatrics Society/British Geriatrics Society (AGS/BGS)
guidance7 in terms of a dose of at least 800 iu daily
together with recommendations of the CMOs of the
UK8 supporting treatment of a UK elderly population,
we evaluated the cost-effectiveness and budget impact of
treating the older adult (age 60 years and above) UK
population with at least 800 iu of vitamin D daily with
regard to its impact on falls.
METHODS
A Markov health state transition model was constructed
in Microsoft Excel to simulate patient transitions
through a simpliﬁed patient pathway representing the
key fall-related outcomes described in a detailed audit of
UK accident and emergency department (A&E)
records.13 The model conservatively used a 5-year
horizon and annual cycles to assess the costs and bene-
ﬁts of treatment with colecalciferol 800 iu daily. The
payer perspective was that of the UK taxpayer taking
National Health Service (NHS) and Social Care expend-
iture into account.
Health states
As described in ﬁgure 1, patients enter the model in the
‘Well’ state, and during each cycle it was assumed they
lived in an independent community setting. During
each cycle patients could experience either: (1) a
‘Minor fall’, necessitating A&E attendance but no admis-
sion and either no follow-up, outpatient follow-up or
general practitioner (GP) follow-up; or (2) a ‘Major fall’
with admission to hospital via A&E and either discharge
to home with follow-up or transfer to postacute care; or
(3) death. Those experiencing a minor fall were
assumed to make a full recovery as were those who had
a major fall but did not require postacute care or died
in hospital. Patients transferred to postacute care could
return to independent living in their ﬁrst year, there-
after the remainder were assumed to require long-term
residential or nursing care.
Health state transitions
Annual rates of accident and emergency admission were
used to deﬁne age-group dependent probability of
minor and major unintentional falls.13 These were
derived by Scuffham et al, from a detailed analysis of UK
sentinel databases are used to record mode of arrival at
A&E, circumstances of the accident (cause), injury sus-
tained, and deployment (eg, referral to GP). It was con-
servatively assumed that: each patient experiences just
one fall event in a given year; and that future probability
of falling is not conditional on fall history. Acute phase
outcomes following admission for a major fall (death
and discharge to post-acute care) were also deﬁned.13
Age-group dependent all-cause mortality was applied
equally to those remaining fall-free and those recovering
fully from either a minor or major fall.14 For those in
long-term care, the death rate observed by Bebbington
et al15 during their longitudinal survey of 2540 admitted
residents from 18 local authorities was conservatively
applied. The probability of returning home in the ﬁrst
year after admission to long-term care was also applied
from the Bebbington study. The transitions are sum-
marised in table 1.
Treatment
The intervention under consideration is empiric treat-
ment of all older adults aged 60 years and over with
colecalciferol 800 iu daily. While this considers the older
adult cohort preceding that recommended by the UK
Figure 1 Markov health state transition model representing
unintentional falls in older people. Key: ‘Well’, No fall in cycle
and living at home; ‘Minor fall’, Fall resulting in A&E
attendance but no admission; ‘Major fall’, Fall resulting in
hospital admission; ‘Care’, No fall in cycle and living in care
facility; and ‘Death’, from any cause. A&E, accident and
emergency.
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chief medical ofﬁcers,8 it takes in the age cohorts exam-
ined by Scuffham et al13 with respect to falling, thus pro-
viding evidence to where the economic boundary of
‘older’ adulthood may lie with respect to fall prevention.
The daily dose of colecalciferol administered is higher
than the 400 iu jointly recommended by the UK CMOs
because daily doses less than 700 iu have been shown to
be ineffective in preventing falls in older adults, while
patients treated with between 700 and 1000 iu have a
shown a lower relative risk of falling (RR 0.81 (95% CI
0.71 to 0.92)).6 This treatment effect was applied equally
to falls of any severity. The comparator was assumed to
be current standard of care.
In terms of adverse effects of treatment we assumed
none associated with vitamin D 800 iu daily treatment in
line with the recent US Preventative Services Task Force
ﬁnding of adequate evidence that the harms of treat-
ment of vitamin D deﬁciency are small to none.16
Costs
Within our model, we selected the price of only licensed
800 iu vitamin D formulations available for prescription
in the UK. We chose these preparations as there is a spe-
ciﬁc NHS tariff making calculations straightforward but
also the Medicines and Healthcare Products Regulatory
Agency (MHRA) stipulate that where a licensed product
exists, unlicensed products should not be used.17
Therefore daily colecalciferol 800 iu treatment was
assumed to be met by proprietary oral capsules as the
lowest cost option in the British National Formulary
(BNF).18 Fall-related costs were those listed13 and
indexed to 2014 prices.19 All costs are summarised in
table 2.
Utilities
Baseline utility in the ‘Well’ state was deﬁned according
to 5-year age group and the UK value set for the
EQ-5D-3 L.20 Falls were assumed to confer a disutility
associated with severe fear of falling.21 Postacute institu-
tional care was also associated with disutility compared to
age-gender matched counterparts reported in a study of
Australian older adults.22 Hospital admission following a
major fall was conservatively assumed to incur the same
disutility as postacute care for 10 days, the average length
of stay for HRG R29.6, Tendency to fall, not elsewhere classi-
ﬁed.23 Utilities are summarised in table 3.
Budget impact population
Budget impact calculations were based on the older
adult population of the UK at the 2011 census.24
RESULTS
Outcomes
Over the 5-year model horizon, our model suggests that
empiric colecalciferol treatment at 800 iu daily among
Table 1 Transition probabilities between Markov health states (see figure 1)
Transition Description Source
Age group (%)
60–64 65–69 70–74 ≥75
A Probability of minor fall Scuffham 2.4 2.4 2.8 5.8
B Probability of major fall Scuffham 0.3 0.5 0.9 3.7
C Probability of long-term care following major fall Scuffham 0.0 0.0 8.6 27.4
D Probability of death following major fall Scuffham 0.2 0.4 0.7 1.0
E Recovery following minor fall Assumption 100.0 100.0 100.0 100.0
F Recovery following major fall 1-C-D 99.8 99.6 90.7 71.7
G Probability of death while in care Bebbington* – – 20.6 20.6
H Probability of death from independent living ONS 0.6 0.6 1.6 7.5
I Probability of return to independent living Bebbington† – – 3.8 3.8
*Conservatively estimated as that applicable to residential care.
†93/2450 older adults admitted to institutional care observed over 42 months. As the survival distribution of ‘returners’ is unknown the model
conservatively estimates that they occur in the first year only following a major fall.
Table 2 Costs to NHS relating to falls and vitamin D
treatment
Description GBP2014 Source
Annual cost of daily vitamin D
800 IU supplementation
£43.83 BNF
Ambulance journey £306 Scuffham
GP consultation £31
A&E attendance £111
Return to residence, attend OP £116
Return to residence, attend GP £31
Long-term care (6 months) £16 388
Minor fall (weighted)
60–64 £442
65–69 £456
70–74 £466
≥75 £462
Major fall (weighted HRG acute
costs)
60–64 £2622
65–69 £2766
70–74 £3603
≥75 £3537
A&E, accident and emergency; BIM, Budget Impact Model;
BNF, British National Formulary; GP, general practitioner;
HRG, Healthcare Resource Group; NHS, National Health Service;
ONS, Office of National Statistics; OP, outpatients.
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older adults aged 60 years and over in the UK would:
(1) prevent in excess of 430 000 minor falls; (2) avoid
190 000 major falls; (3) prevent 1579 acute deaths; (4)
avoid 84 000 person-years of long-term care; and (5)
avoid a further 8300 deaths associated with increased
mortality in long-term care (table 4). The greatest gains
are seen among those aged 75 years and older which
would account for 51% of preventable minor falls, 75%
of preventable major falls, 96% of person years in care
avoided and 94% avoidable attributable mortality.
Cost-effectiveness
Compared to current care, treating all adults aged
60 years and over with colecalciferol 800 iu daily would
have an incremental cost-effectiveness ratio of £19 759
per quality adjusted life year (QALY) gained based on a
reduction in falls alone. The same intervention in all
adults aged 65 years and over, as recommended by the
UK CMOs8 dominates current care, by being cost-saving
and leading to increased QALYs (table 5).
Budget impact
The costs and net budget impact of alternative age-
bound strategies for use of empiric maintenance treat-
ment with colecalciferol 800 iu daily are shown in
table 6. Treating all adults aged 60 years and over, would
incur an intervention cost of £2.70bn over 5 years, yet
over the same period a −£3.12bn reduction in fall-
related costs would produce a net saving of £420M.
Increasing the lower bound age limit by 5-year incre-
ments increases budget impact to −£1.17bn, −£1.75bn
and −£2.06bn for intervention strategies applied to all
adults aged 65+, aged 70+ and aged 75+, respectively
(ﬁgure 2).
DISCUSSION
Our study shows that treating all adults over the age of
65 with vitamin D at doses of 800 iu daily would result in
a substantial cost-saving to the UK NHS of £1.2 billion
over 5 years through prevention of some 530 000 falls,
84 000 person-years in long-term care, and almost
10 000 premature deaths. Additionally, the empiric treat-
ment of younger seniors from the age of 60 would also
be cost-saving, albeit less so. The main relief of burden
on health and social care expenditure would arise from
avoidance of long-term care following a fall in those
aged 70 years and over. These data are consistent with
cost-effectiveness assessments of universal vitamin D sup-
plementation in older adults in the USA9 and also in
Western European populations but using fractures as the
primary modiﬁable outcome.10 11
The ‘memory-less’ property of our Markov model
structure introduced a conservative assumption that fall
history does not inﬂuence future risk of falling.
Additionally, falls among those receiving long-term care
was not modelled. Our model also applied all-cause
mortality as the background death rate, which include
deaths from unintentional falls, effectively reducing the
Table 3 Health state utilities by age-group
Health
state Source
Age group
60–64 65–69 70–74 ≥75
Well Kind et al20 0.800 0.780 0.780 0.730
Minor fall Thiem et al21 0.783 0.763 0.763 0.713
Major fall 0.768 0.748 0.748 0.698
Long-term
care
Couzner et al22 0.606 0.586 0.586 0.536
Table 4 Comparison of 5-year fall-related outcomes for
current care versus empiric vitamin D maintenance therapy
Age group Current Vitamin D Δ
Minor falls
60–64 449 271 363 910 85 360
65–69 350 460 283 875 66 585
70–74 328 891 266 484 62 407
≥75 1 190 867 968 252 222 615
Major falls
60–64 64 769 52 463 12 306
65–69 77 452 62 737 14 715
70–74 109 630 88 828 20 802
≥75 761 374 619 046 142 328
Deaths from falls
60–64 149 121 28
65–69 333 270 63
70–74 713 577 135
≥75 7233 5881 1352
Person-years in care
60–64 – – –
65–69 – – –
70–74 18 338 14 857 3481
≥75 426 696 346 408 80 288
Deaths from care
60–64 – – –
65–69 – – –
70–74 1932 1566 367
≥75 42 586 34 625 7961
Table 5 Cost-effectiveness results of alternative
treatment strategies (per person treated)
Strategy
Incremental
costs
Incremental
QALYs ICER
Treat all adults
≥60 years
£23.52 0.0012 £19 759
Treat all adults
≥65 years
−£34.19 0.0014 Dominant
Treat all adults
≥70 years
−£147.01 0.0018 Dominant
Treat all adults
≥75 years
−£419.88 0.0027 Dominant
ICER, incremental cost-effectiveness ratio; QALY, quality adjusted
life year.
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‘at-risk’ population. Therefore our estimates of cost-
effectiveness are likely conservative.
Sustainability of treatment effect is an important con-
sideration in any economic analysis. Active forms of
vitamin D, including colecalciferol, do not need hydrox-
ylation in the kidney, so their effect on falls should be
inﬂuenced less by age-related decline in kidney function
than the effect of supplemental vitamin D. The duration
of the eight randomised controlled trials included in the
primary efﬁcacy meta-analysis we modelled,6 was 2, 3, 5,
12, 20, 24 and 36 months suggesting that the pooled
effect is consistent over longer time periods. In addition
we conservatively set a model horizon of 5 years to avoid
speculative extrapolation of long-term beneﬁts with
increasing uncertainty.
Falls are a particularly common problem in the
elderly person accounting for 10% of emergency hos-
pital visits and 6% of hospital admissions with risk
increasing with increasing age.25 Rather than a benign
process, falls are a predictor of increasing morbidity,
mortality and importantly institutionalisation. In conse-
quence, falls present a signiﬁcant risk to health and are
costly. We based our calculations on the health eco-
nomic evaluation of falls in the UK.13 This data included
the cost of falls to the NHS and social care budgets.
While our calculated cost-savings are great, the estimates
used to support these calculations have been conserva-
tive. Indeed, the older person who has fallen suffers
greater decline in activities of daily living as well as
greater risk of institutionalisation.26 Those who return to
independent living following a fall often require domes-
tic care support, costs we did not factor in our evalu-
ation. With this in mind, we have demonstrated that
800 iu colecalciferol daily is a cost-effective treatment
purely based on fall prevention in individuals 60 years
and over. The cost per QALY of £19 759 is within the
expected economic cost per QALY threshold of £20 000
advocated by the National Institute of Care Excellence
Table 6 Budget impact on NHS for alternative age-bound empiric vitamin D maintenance therapy strategies
Strategy Well Minor fall Major fall Care after major fall Long-term care Total Net BIM
Current care
All 60+ £ M £1062 M £3472 M £3540 M £9378 M £17 451 M
All 65+ £ M £863 M £3302 M £3540 M £9378 M £17 083 M
All 70+ £ M £703 M £3088 M £3540 M £9378 M £16 709 M
All 75+ £ M £550 M £2693 M £3386 M £8994 M £15 623 M
Empiric vitamin D maintenance
All 60+ £2703 M £944 M £2857 M £2886 M £7642 M £17 032 M −£420 M
All 65+ £1903 M £767 M £2717 M £2886 M £7642 M £15 915 M −£1168 M
All 70+ £1270 M £626 M £2540 M £2886 M £7642 M £14 963 M −£1746 M
All 75+ £771 M £490 M £2216 M £2761 M £7330 M £13 567 M −£2056 M
NHS, National Health Service.
£M
All 60+ All 65+ All 70+ All 75+
–£420 M
–£1168 M
–£1746M
–£2056 M
–£500 M
–£1000 M
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–£2500M
Figure 2 Budget impact results for alternative treatment strategies.
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(NICE). This is comparable to evaluations for the pre-
vention of ischaemic heart disease with statin therapy.27
Similarly, dominant QALY costs, (indicating that there
are net savings accrued through fall prevention with
vitamin D treatment), were noted with the application
of the recommendations of the CMOs letter8 for the
treatment of all patients aged 65 years and over (table
5).
Vitamin D is an important sterol hormone involved in
calcium metabolism with recognition of its important
role in musculoskeletal health. Evidence reveals that
vitamin D deﬁciency is common in the UK with studies
suggesting a prevalence as high as 50%28 and even
higher in certain populations such as the elderly and
institutionalised.29 Decreased bone mineralisation,
increased fracture risk as well as increased risk of falls
are associated with vitamin D deﬁciency30–32 and evi-
dence would point to the improvement in some of these
parameters following treatment, particularly in the
elderly.3 6 33 However, not all studies conclude a reduc-
tion in falls and such discrepancies may be a conse-
quence of the use of different formulations
(ergocalciferol or colecalciferol), different doses of
vitamin D, differing baseline vitamin D status and also
differing populations.5 34 However, guidelines on fall
prevention has evaluated the evidence and support the
treatment of individuals with deﬁciency, or potential
deﬁciency, at risk of falls with at least 800 iu of vitamin D
daily.7 Similarly, UK CMOs also advocate vitamin D treat-
ment, yet the 400 iu dose advocated may be ineffective
in terms of preventing deﬁciency, falls and fractures in
an elderly population.3 6 In consequence, we elected an
800 iu dose as the minimal, guidance-advocated dose for
fall prevention in the elderly.
The importance of vitamin D in an adult population
can be seen at the extreme end of the clinical spectrum
as osteomalacia, with pseudofractures and profound
proximal muscle weakness. Symptoms and signs resolve
following treatment and so it seems plausible that
vitamin D therapy too has beneﬁcial effects in non-
osteomalacic vitamin D deﬁciency.35 This is supported
by studies revealing dose dependent reduction in falls
and fractures3 6 33 which may accrue only with vitamin D
deﬁciency/insufﬁciency, a common problem in the
elderly population. Factors contributing to the reduced
risk of falls following vitamin D treatment include
improved muscle strength36 37 as well as improved
balance.34 Indeed, improved muscle mitochondrial oxi-
dative function38 as well as muscle energy metabolism39
following vitamin D treatment may provide mechanistic
explanations for improved strength and endurance.
Histologically, reduced muscle ﬁbre number and
changes in muscle ﬁbre type my contribute further to
the sarcopaenia and myopathy found with aging and
vitamin D deﬁciency40 and may improve following treat-
ment with vitamin D.41
Our study also shows that the reduced risk of falls asso-
ciated with treating an elderly population with vitamin D
is associated with a substantial reduction in premature
deaths. Studies reveal increased mortality associated with
lower 25OHD concentrations although this relationship
has been considered to be an epiphenomenon of
illness. However, recent data support the role of reduced
mortality following vitamin D treatment.42–45 In particu-
lar, colecalciferol rather than ergocalciferol appears to
offer superiority in mortality reduction.44 The single
ﬁgure per cent reduction in mortality seen in such
studies is in keeping with that calculated in our study.
With respect to UK public health policy regarding
vitamin D supplementation in older adults,8 we believe,
in light of the clinical and economic evidence, that the
current advice is ﬂawed. First, the recommendation of
universal supplementation of colecalciferol 400 iu
(10 µg) daily has been shown to be ineffective in the
prevention of either falls6 or fractures.3 Expert guide-
lines suggest a minimum daily supplement of 800 iu in
those at risk.7 Second, the optimal method of procure-
ment is not clearly stated, with OTC supply being given
equal weighting to prescription. We contend that pre-
scribed therapy should be favoured over OTC prepara-
tions, not just on the grounds of quality and safety18 but
also as a means of improving patient compliance with
treatment19 and ensuring equity of access to all older
adults who remain exempt from prescription charges
across the UK.
In conclusion, our data show that with only reference
to fall prevention, the provision of empiric colecalciferol
therapy to all older adults in the UK potentially offers
considerable cost-saving to the UK NHS over a 5-year
horizon. Accompanying such ﬁnancial beneﬁts, a reduc-
tion in attributable premature mortality and increase in
quality-adjusted life years could also be expected.
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